NCT05112991

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 108 (estimated)
• Sponsor: 3D Medicines (Sichuan) Co., Ltd. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.

Conditions

• Advanced Endometrial Cancer

Interventions

Type	Name	Description
DRUG	Envafolimab+Lenvatinib	Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle. Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle.
DRUG	Envafolimab	Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.

Timeline

• Start date: 2022-03-04
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2021-11-09
• Last updated: 2026-03-25

Locations

19 sites across 1 country: China